PTIX - רווח נקי למניה (EPS TTM) protagenic.com

Protagenic Therapeutics (PTIX) is protected by patents for PT00114 peptides and a powerful lobby, despite stringent FDA oversight. The change in rolling net income per share provided by the GURU.Markets system demonstrates a trend where -7.18 forms the current metric value. The business model relies on future superprofits from the serial production of drugs, although risks remain regarding potential test failures and liquidity shortages.

The fundamental value of Protagenic Therapeutics (PTIX) is determined by its ability to generate real earnings per share. By analyzing the TTM earnings per share trend, an investor sees the net financial result for the year, stripped of the influence of the total issuance volume. This indicator filters out market noise, capturing business expansion phases. For Protagenic Therapeutics (PTIX), the automation of neuropeptide synthesis must translate into growth for this metric. A positive trend would confirm the effectiveness of its bioinformatics platforms.